Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | CDK7 | P50613 | 1/20 | 0.62 |
| ▸ | CCNH | P51946 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14877794 | 0.88 | CA12 (0.76) | PGRCYP19A1CA12CA1CA2 | |
| SCHEMBL3791521 | 0.85 | PGR (0.81) | PGRCYP19A1ALOX15PKMALDH1A1 | |
| SCHEMBL3701951 | 0.85 | CA12 (0.71) | CYP19A1CA12CA1CA2CA9 | |
| SCHEMBL26463794 | 0.84 | CYP19A1 (0.78) | PGRCYP19A1ALOX15CA12CA1 | |
| SCHEMBL343776 | 0.84 | HTR6 (0.73) | PGRCYP19A1ALOX15CA1CA2 | |
| SCHEMBL29561272 | 0.83 | PGR (0.67) | PGRCYP19A1ALOX15PKMALDH1A1 | |
| SCHEMBL9001319 | 0.82 | CA1 (0.67) | PGRCYP19A1CA12CA1CA2 | |
| SCHEMBL19336603 | 0.81 | GPR27 (0.67) | ALOX15PKMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16900686 | 0.81 | CA12 (0.65) | PGRCYP19A1CA12CA1CA2 | |
| SCHEMBL6607079 | 0.81 | ALDH1A1 (0.71) | CYP19A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975399-B2 | Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF | VAX-CONSULTING (FR) | 2015-03-10 | — | — | US | disclosed |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | VAX-CONSULTING (FR) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | TNF, TNFRSF1A, TRAF6 | PGR 892/4885CYP19A1 733/4885ALOX15 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.